Literature DB >> 24927312

Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial.

A Hale Jean-Michel Azorin Siegfried Kasper Wolfgang Maier Erkka Syvalahti Michael Van Der Burght Mogens Sloth-Nielsen Allan Wehnert.   

Abstract

OBJECT: The objective of this double-blind, multicentre study was to evaluate four doses of sertindole and haloperidol 10 mg.
METHOD: The 617 schizophrenic patients were randomized to receive sertindole 8, 16, 20 or 24 mg/day or haloperidol 10 mg/day. Patients were assessed for extrapyramidal symptoms (EPS) using the Simpson-Angus Scale (SAS) and Barnes Akathisia Scale (BAS), and for movement disorders using the Abnormal Involuntary Movement Scale (AIMS).
RESULTS: Patients receiving haloperidol experienced significantly more EPS than patients receiving sertindole, supporting observations made in previous studies. The incidence of adverse events was similar for all doses of sertindole. SAS and BAS scores were significantly worse in the haloperidol group than in the sertindole groups. There were significantly greater increases in mean QT c interval in the sertindole groups than in the haloperidol group. Sertindole did not cause sedation.
CONCLUSIONS: Sertindole is well tolerated and does not cause the debilitating EPS associated with traditional antipsychotic drugs. (Int J Psych Clin Pract 2000; 4:47-54).

Entities:  

Keywords:  Antipsychotic Agents Phase Iii Clinical Trial Sertindole Extrapyramidal Symptoms Schizophrenia

Year:  2000        PMID: 24927312     DOI: 10.1080/13651500052048758

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  4 in total

1.  Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.

Authors:  Marc De Hert; Aurélia Mittoux; Yuan He; Joseph Peuskens
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-09-05       Impact factor: 5.270

2.  The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.

Authors:  Siegfried Kasper; Hans-Jürgen Möller; Anthony Hale
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-05-20       Impact factor: 5.270

Review 3.  Sertindole : a review of its use in schizophrenia.

Authors:  David Murdoch; Gillian M Keating
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Sertindole for schizophrenia.

Authors:  R Lewis; A-M Bagnall; M Leitner
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.